ACRS - Aclaris Therapeutics, Inc.
| Previous Close | 1.6100 |
| Open | 1.6200 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 900 |
| Day's Range | 1.5500 - 1.6500 |
| 52 Week Range | 0.7400 - 12.9000 |
| Volume | 812,438 |
| Avg. Volume | 1,872,300 |
| Market Cap | 68.258M |
| Beta (3Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.1680 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- Zacks
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
- American City Business Journals
Wayne biopharma sells rosacea therapy in deal that could bring in $55M
The Chester County biopharmaceuticals sold its Rhofade cream as part of its plan to focus it resources on developing products immuno-inflammatory diseases.
- GlobeNewswire
Aclaris Therapeutics Announces Divestiture of RHOFADE®
Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE® (oxymetazoline hydrochloride) cream, 1% (RHOFADE) and related intellectual property assets to EPI Health, LLC (EPI Health). The divestiture of RHOFADE is a key component of Aclaris’ recently announced strategic plan to refocus resources on the development of its immuno-inflammatory development programs. Aclaris and EPI Health have entered into a purchase agreement whereby Aclaris sold the worldwide rights to RHOFADE, which includes the assignment of certain licenses for related intellectual property assets.
- Benzinga
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks ...
- GlobeNewswire
Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%
WAYNE, Pa., Oct. 08, 2019 -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that.
- Thomson Reuters StreetEvents
Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 Aclaris Therapeutics Inc Earnings Call
- Simply Wall St.
Does Market Volatility Impact Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Share Price?
Anyone researching Aclaris Therapeutics, Inc. (NASDAQ:ACRS) might want to consider the historical volatility of the...
- GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm
NEW YORK, Oct. 06, 2019 -- Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (NASDAQ: PSMT), Pyxus International, Inc. (NYSE: PYX),.
- Zacks
Top Ranked Momentum Stocks to Buy for October 3rd
Top Ranked Momentum Stocks to Buy for October 3rd
- ACCESSWIRE
FINAL DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 30, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ:ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA's Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris's hydrogen peroxide topical solution, Eskata, "makes false or misleading claims" about its risk and efficacy.
- GlobeNewswire
FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action – ACRS
NEW YORK, Sept. 30, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8,.
- ACCESSWIRE
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 28, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ:ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA's Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris's hydrogen peroxide topical solution, Eskata, "makes false or misleading claims" about its risk and efficacy.
- Business Wire
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (ACRS) securities between May 8, 2018 and June 29, 2019 (the “Class Period”). Investors have until September 30, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- ACCESSWIRE
FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ:ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA's Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris's hydrogen peroxide topical solution, Eskata, "makes false or misleading claims" about its risk and efficacy.
- GlobeNewswire
Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
- Zacks
Top Ranked Momentum Stocks to Buy for September 27th
Top Ranked Momentum Stocks to Buy for September 27th
- GlobeNewswire
DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
- ACCESSWIRE
Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can ...
- PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS
NEW YORK, Sept. 26, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and indexed under 19-cv-08284, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired publicly traded Aclaris securities between May 8, 2018, and June 20, 2019, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act"). If you are a shareholder who purchased Aclaris securities during the class period, you have until September 30, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.
- GlobeNewswire
Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. – ACRS
Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of Aclaris Therapeutics, Inc. (ACRS) from May 8, 2018 through June 20, 2019, inclusive (the “Class Period”). To express an interest in the class action, go to http://pawarlawgroup.com/cases/aclaris-therapeutics-inc/ or call Vik Pawar, Esq.
- Zacks
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).
- PR Newswire
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm
NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (ACRS) securities between May 8, 2018 and June 29, 2019 (the "Class Period"). Investors have until September 30, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Newsfile
ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - September 25, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) ("Aclaris" or the "Company") of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you invested in Aclaris stock or options between May 8, 2018 and June 20, 2019 and ...
